Last updated: 11/17/2026 12:40:24
Shingrix for Intramuscular Injection Drug Use Investigation
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Trial overview
Official title: Shingrix for Intramuscular Injection Drug Use Investigation
Trial description: The purpose of this prospective, descriptive, multi-center, drug utilization study was to assess the safety of Shingrix vaccine when administered in Japanese adults ≥50 Years of Age (YOA) for the first time.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Occurrence of adverse drug reactions (ADRs) (solicited adverse events), overall, by seriousness and by severity
Timeframe: During the 7-day follow-up period after vaccination (day of vaccination designated as Day 1) for each participant (observation period), collected between August 2020 to March 2025 (investigation period)
Occurrence of ADRs (unsolicited adverse events), overall, by seriousness and by severity
Timeframe: During the 30-day follow-up period after vaccination (day of vaccination designated as Day 1) for each participant (observation period), collected between August 2020 to March 2025 (investigation period)
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
7830
Primary completion date:
2025-18-11
Observational study model:
Other
Time perspective:
Prospective
Clinical publications:
Not applicable
- Participants vaccinated with Shingrix for the first time.
- Obtaining informed consent from vaccinated person (and/or person’s representative).
- None
Inclusion and exclusion criteria
Inclusion criteria:
- Obtaining informed consent from vaccinated person (and/or person’s representative).
Participants vaccinated with Shingrix for the first time.
Exclusion criteria:
None
Trial location(s)
Study documents
Study report synopsis
Available language(s): English
Clinical study report
Available language(s): English
Protocol
Available language(s): English
Statistical analysis plan
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Finalized
Actual primary completion date
2025-18-11
Actual study completion date
2025-18-11
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website